Hormonal
Semaglutide at its maximum tolerated dose (MTD) is associated with the highest odds of treatment discontinuation due to adverse events among all tested regimens, including tirzepatide MTD.
If you choose semaglutide at its maximum dose, be aware that you have the highest statistical risk of stopping the medication due to side effects compared to other options in this study. Monitor your tolerance closely and communicate with your provider immediately if side effects become unmanageable.
The highest odds of treatment discontinuation due to adverse events were observed with semaglutide MTD (odds ratio (OR): 7.36; 95% CI: 2.56 to 21.15) and tirzepatide MTD (OR: 5.56; 95% CI: 2.28 to 13.58).
Why this rating
Based on network meta-analysis of RCTs; no heterogeneity detected for this specific outcome.
Source
Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials
Alousious Kasagga et al. · Cureus · 2025
DOI 10.7759/cureus.90335
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →